[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_9538",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_9538"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB08889"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "kyprolis is a proteasome inhibitor that is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy 1 14 as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy 1 14 kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB08889",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-12T14:54:49.698+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "NxxsLEtdJs5vMx86r8GDwy5PKJANRgBWxXugAxiVedIKqOYzo1gpCrPeEbmy/zSfwkkJHrl2z5y+FKA9+iLScF4pOthcgmcEFrlHArH1Bw4cIWNkCvfgrLrVzCBOIJsriU28HSV/+2+h+Jbm/D+sNTL3aWmz2oVvDdoVM61t+R0="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA0S2JEO7jRxcePUbpUK2PN_IhQvKG9hSWyCRjW4OAgt4#pubinfo"
} ]